Federated Hermes
KZR

Federated Hermes’s Kezar Life Sciences KZR Stock Holding History

Federated Hermes’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-623
Closed -$4.81K – 2142
2024
Q3 		$4.81K Sell
623
-272
-30% -$1.64K ﹤0.01% 1863
2024
Q2 		$5.37K Sell
895
-1,453
-62% -$11K ﹤0.01% 1833
2024
Q1 		$21.2K Buy
2,348
+306
+15% +$2.79K ﹤0.01% 1715
2023
Q4 		$19.3K Sell
2,042
-719
-26% -$6.32K ﹤0.01% 1750
2023
Q3 		$32.9K Buy
2,761
+256
+10% +$4.54K ﹤0.01% 1717
2023
Q2 		$61.4K Buy
2,505
+2,333
+1,356% +$60.7K ﹤0.01% 1655
2023
Q1 		$5.37K Buy
+172
New +$9.95K ﹤0.01% 1926
2022
Q2 		– Sell
-4,866
Closed -$809K – 2228
2022
Q1 		$809K Sell
4,866
-41
-0.8% -$5.88K ﹤0.01% 1314
2021
Q4 		$820K Buy
4,907
+4,234
+629% +$478K ﹤0.01% 1350
2021
Q3 		$58K Buy
+673
New +$44.5K ﹤0.01% 1849
2020
Q1 		– Sell
-16
Closed -$1K – 2303
2019
Q4 		$1K Hold
16
– – ﹤0.01% 2106
2019
Q3 		$1K Buy
+16
New +$773 ﹤0.01% 2110
2019
Q2 		– Sell
-26
Closed -$5K – 2192
2019
Q1 		$5K Buy
26
+6
+30% +$1.18K ﹤0.01% 1972
2018
Q4 		$5K Buy
+20
New +$4.89K ﹤0.01% 1980

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Federated Hermes's KZR Position: Q4 2024 in Review

Federated Hermes sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 623 shares — an estimated $4.81K sold.

Federated Hermes first reported a position in KZR in Q4 2018 and held it in 14 quarters. The position peaked at $820K in Q4 2021. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.

  • Federated Hermes reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 623 Kezar Life Sciences shares in Q4 2024, an estimated $4.81K.
  • Federated Hermes first reported a position in Kezar Life Sciences in Q4 2018 and held it in 14 quarters.
  • Federated Hermes's Kezar Life Sciences position peaked at $820K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.